BR112013004850A2 - tratamento de infarto do miocárdio usando antagonistas tgf-beta - Google Patents

tratamento de infarto do miocárdio usando antagonistas tgf-beta

Info

Publication number
BR112013004850A2
BR112013004850A2 BR112013004850A BR112013004850A BR112013004850A2 BR 112013004850 A2 BR112013004850 A2 BR 112013004850A2 BR 112013004850 A BR112013004850 A BR 112013004850A BR 112013004850 A BR112013004850 A BR 112013004850A BR 112013004850 A2 BR112013004850 A2 BR 112013004850A2
Authority
BR
Brazil
Prior art keywords
myocardial infarction
tgf
treatment
beta antagonists
patient
Prior art date
Application number
BR112013004850A
Other languages
English (en)
Other versions
BR112013004850B1 (pt
Inventor
Amelia B Kudej
Georffrey Y Akita
Richard C Gregory Jr
Scott Lonning
Original Assignee
Genzyme Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Genzyme Corp filed Critical Genzyme Corp
Publication of BR112013004850A2 publication Critical patent/BR112013004850A2/pt
Publication of BR112013004850B1 publication Critical patent/BR112013004850B1/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/22—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against growth factors ; against growth regulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2121/00—Preparations for use in therapy
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/475—Growth factors; Growth regulators
    • C07K14/495—Transforming growth factor [TGF]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Immunology (AREA)
  • Molecular Biology (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Biochemistry (AREA)
  • Microbiology (AREA)
  • Genetics & Genomics (AREA)
  • Urology & Nephrology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Mycology (AREA)
  • Biophysics (AREA)
  • Endocrinology (AREA)
  • Biomedical Technology (AREA)
  • Biotechnology (AREA)
  • Cardiology (AREA)
  • Hematology (AREA)
  • Vascular Medicine (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cell Biology (AREA)
  • Diabetes (AREA)
  • General Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Physics & Mathematics (AREA)
  • Food Science & Technology (AREA)
  • Rheumatology (AREA)
  • Analytical Chemistry (AREA)

Abstract

tratamento de infarto do miocárdio usando antagonistas tgf-beta. a presente invenção refere-se a um método de tratamento de um paciente que sofre de um infarte do miocárdio, particularmente infarte do miocárdio agudo, ou de reduzir a consequência adversa de um infarte do miocárdio em um paciente, compreendendo a administração de um antagonista do tgf-<225> para o paciente durante a fase aguda de infarto do miocárdio.
BR112013004850A 2010-09-01 2011-09-01 uso de um antagonista do tgf-b na preparação de um medicamento para tratamento de infarto do miocárdio BR112013004850B1 (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US37931510P 2010-09-01 2010-09-01
PCT/US2011/001536 WO2012030394A1 (en) 2010-09-01 2011-09-01 Treatment of myocardial infarction using tgf - beta antagonists

Publications (2)

Publication Number Publication Date
BR112013004850A2 true BR112013004850A2 (pt) 2016-05-31
BR112013004850B1 BR112013004850B1 (pt) 2020-04-07

Family

ID=44654454

Family Applications (1)

Application Number Title Priority Date Filing Date
BR112013004850A BR112013004850B1 (pt) 2010-09-01 2011-09-01 uso de um antagonista do tgf-b na preparação de um medicamento para tratamento de infarto do miocárdio

Country Status (18)

Country Link
US (2) US20130330352A1 (pt)
EP (1) EP2611831B1 (pt)
JP (2) JP6377348B2 (pt)
KR (1) KR101939965B1 (pt)
CN (1) CN103201292B (pt)
BR (1) BR112013004850B1 (pt)
CA (1) CA2809568C (pt)
CL (1) CL2013000586A1 (pt)
ES (1) ES2715177T3 (pt)
IL (1) IL225018A (pt)
MX (1) MX354535B (pt)
MY (1) MY165160A (pt)
NZ (2) NZ608813A (pt)
PL (1) PL2611831T3 (pt)
RU (1) RU2637088C2 (pt)
SG (2) SG10201506909PA (pt)
TR (1) TR201903101T4 (pt)
WO (1) WO2012030394A1 (pt)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2012518041A (ja) * 2009-02-18 2012-08-09 コーマトリックス カーディオバスキュラー， インコーポレイテッド 心不整脈を予防するための組成物および方法
TWI664979B (zh) 2013-03-11 2019-07-11 健臻公司 經生物工程之抗-ＴＧＦ-β抗體及抗原結合片段
AU2014308751B2 (en) 2013-08-22 2020-03-05 Acceleron Pharma, Inc. TGF-beta receptor type II variants and uses thereof
US11384350B2 (en) 2014-12-15 2022-07-12 The Regents Of The University Of California Cytotoxic molecules responsive to intracellular ligands for selective T cell mediated killing
WO2016100232A1 (en) 2014-12-15 2016-06-23 The Regents Of The University Of California Bispecific or-gate chimeric antigen receptor responsive to cd19 and cd20
AU2016301380B2 (en) 2015-08-04 2021-07-01 Acceleron Pharma Inc. Methods for treating myeloproliferative disorders
CN108884155B (zh) * 2015-10-30 2022-12-06 加利福尼亚大学董事会 转化生长因子-β应答多肽及其使用方法
WO2017123550A1 (en) * 2016-01-11 2017-07-20 Autotelic Llc Composition, device, and method for detecting olmesartan and improving compliance in treating hypertension
US20170218040A1 (en) * 2016-02-02 2017-08-03 Julio A. Camarero Palao Proteolically resistant cyclotides with angiotensin 1-7 like activity
EP3496755A4 (en) * 2016-08-11 2020-03-11 Precithera, Inc. CONJUGATES OF TGF- ANTAGONISTS.
LT3628049T (lt) 2017-05-04 2023-08-25 Acceleron Pharma Inc. Tgf-beta ii tipo receptoriaus sulieti baltymai ir jų panaudojimo būdai
AU2022355276A1 (en) 2021-09-30 2024-05-16 Peptidream Inc. Peptide

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB8308235D0 (en) 1983-03-25 1983-05-05 Celltech Ltd Polypeptides
US4816567A (en) 1983-04-08 1989-03-28 Genentech, Inc. Recombinant immunoglobin preparations
JPS61134325A (ja) 1984-12-04 1986-06-21 Teijin Ltd ハイブリツド抗体遺伝子の発現方法
GB8607679D0 (en) 1986-03-27 1986-04-30 Winter G P Recombinant dna product
US5571714A (en) 1988-12-22 1996-11-05 Celtrix Pharmaceuticals, Inc. Monoclonal antibodies which bind both transforming growth factors β1 and β2 and methods of use
GB9015198D0 (en) 1990-07-10 1990-08-29 Brien Caroline J O Binding substance
ES2156149T3 (es) 1992-12-04 2001-06-16 Medical Res Council Proteinas de union multivalente y multiespecificas, su fabricacion y su uso.
WO2000034784A1 (en) 1998-12-10 2000-06-15 Phylos, Inc. Protein scaffolds for antibody mimics and other binding proteins
US7763580B2 (en) * 1999-01-05 2010-07-27 University Of Utah Research Foundation Methods for treating conditions associated with the accumulation of excess extracellular matrix
WO2005097832A2 (en) * 2004-03-31 2005-10-20 Genentech, Inc. Humanized anti-tgf-beta antibodies
JP2008528626A (ja) 2005-01-31 2008-07-31 マイラン ラボラトリーズ インク． ヒドロキシル化されたネビボロールを含む薬学的組成物
LT1850873T (lt) 2005-02-08 2019-04-10 Genzyme Corporation Antikūnas prieš tgf beta
CN102292124A (zh) * 2009-01-26 2011-12-21 英特芒尼公司 用于治疗急性心肌梗死和相关疾患的方法
ITMI20110376A1 (it) 2011-03-10 2012-09-11 Wilic Sarl Aerogeneratore raffreddato a fluido

Also Published As

Publication number Publication date
NZ608813A (en) 2014-11-28
EP2611831A1 (en) 2013-07-10
ES2715177T3 (es) 2019-06-03
MY165160A (en) 2018-02-28
SG10201506909PA (en) 2015-10-29
RU2637088C2 (ru) 2017-11-29
IL225018A (en) 2017-11-30
KR101939965B1 (ko) 2019-01-18
PL2611831T3 (pl) 2019-05-31
NZ624382A (en) 2015-05-29
SG187953A1 (en) 2013-03-28
CN103201292B (zh) 2016-09-14
US10633437B2 (en) 2020-04-28
EP2611831B1 (en) 2018-12-12
KR20130111550A (ko) 2013-10-10
CL2013000586A1 (es) 2013-08-30
BR112013004850B1 (pt) 2020-04-07
CA2809568C (en) 2019-06-11
RU2013114365A (ru) 2014-10-10
TR201903101T4 (tr) 2019-03-21
JP2013542179A (ja) 2013-11-21
WO2012030394A1 (en) 2012-03-08
AU2011296574A1 (en) 2013-03-21
JP2017193543A (ja) 2017-10-26
MX2013002390A (es) 2013-08-27
CN103201292A (zh) 2013-07-10
MX354535B (es) 2018-03-09
CA2809568A1 (en) 2012-03-08
JP6377348B2 (ja) 2018-08-22
US20130330352A1 (en) 2013-12-12
US20170233465A1 (en) 2017-08-17
AU2011296574B2 (en) 2015-12-03

Similar Documents

Publication Publication Date Title
BR112013004850A2 (pt) tratamento de infarto do miocárdio usando antagonistas tgf-beta
CY1123470T1 (el) Αναστολεις ιβατ για την αγωγη ηπατοπαθειων
EA201390772A1 (ru) Новые соли и полиморфные формы афатиниба
EA201390803A1 (ru) Ингибиторы бромодомена и их применение
EA201692506A2 (ru) Ингибиторы репликации вирусов гриппа
EA201792465A1 (ru) Соединения для лечения спинальной мышечной атрофии
EA201290919A1 (ru) Индазольные соединения и их применение
EA201590371A1 (ru) 1,4-дизамещенные аналоги пиридазина и способы лечения связанных с дефицитом smn состояний
EA201190217A1 (ru) Замещенные 2-ацетамидо-5-арил-1,2,4-триазолоны и их применение
BR112012026767A2 (pt) composto, sal farmaceuticamente aceitável de um composto, composição farmacêutica, método para tratar ou previnir distúrbios, e, uso de um composto ou sal
WO2012062925A3 (en) Compounds and methods for treating pain
EA201491617A1 (ru) Соединения для лечения спинальной мышечной атрофии
EA201492216A1 (ru) Ингибиторы бромодомена и их применение
EA201390428A1 (ru) Композиции и способы лечения легочной гипертензии
EA201100750A1 (ru) Замещенные диоксопиперидинилфталимидные производные
PH12014501991A1 (en) Phenicol antibacterials
EA201200098A1 (ru) Конденсированные имидазолы и содержащие их композиции, предназначенные для лечения паразитарных заболеваний, таких как, например, малярия
BRPI0908635B8 (pt) composto e/ou um sal farmaceuticamente aceitável do mesmo e composição farmacêutica
MY150600A (en) Use of opioid antagonists for treating urinary retention
WO2012158672A3 (en) Compounds for use in treatment of mucositis
EA201291329A1 (ru) Гетероциклические соединения, их получение и их терапевтическое применение
BR112013010136A2 (pt) vacina, composição terapêutica e métodos para o tratamento ou inibição de gliblastoma
EA201590364A1 (ru) Применение орвепитанта, его солей и кристаллических форм и композиций, его содержащих, для лечения зуда
BR112016001948A2 (pt) antagonistas de v1a para tratar distúrbios do sono de desvio de fase
EA201170447A1 (ru) Производные изохинолинона в качестве антагонистов nk3

Legal Events

Date Code Title Description
B07D Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette]
B06F Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette]
B07E Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette]

Free format text: NOTIFICACAO DE ANUENCIA RELACIONADA COM O ART 229 DA LPI

B06U Preliminary requirement: requests with searches performed by other patent offices: procedure suspended [chapter 6.21 patent gazette]
B09A Decision: intention to grant [chapter 9.1 patent gazette]
B16A Patent or certificate of addition of invention granted [chapter 16.1 patent gazette]

Free format text: PRAZO DE VALIDADE: 20 (VINTE) ANOS CONTADOS A PARTIR DE 01/09/2011, OBSERVADAS AS CONDICOES LEGAIS.

B21F Lapse acc. art. 78, item iv - on non-payment of the annual fees in time

Free format text: REFERENTE A 11A ANUIDADE.

B24J Lapse because of non-payment of annual fees (definitively: art 78 iv lpi, resolution 113/2013 art. 12)

Free format text: EM VIRTUDE DA EXTINCAO PUBLICADA NA RPI 2686 DE 28-06-2022 E CONSIDERANDO AUSENCIA DE MANIFESTACAO DENTRO DOS PRAZOS LEGAIS, INFORMO QUE CABE SER MANTIDA A EXTINCAO DA PATENTE E SEUS CERTIFICADOS, CONFORME O DISPOSTO NO ARTIGO 12, DA RESOLUCAO 113/2013.